MX390627B - Uso de pridopidina para el tratamiento de la disminucion funcional. - Google Patents

Uso de pridopidina para el tratamiento de la disminucion funcional.

Info

Publication number
MX390627B
MX390627B MX2019002265A MX2019002265A MX390627B MX 390627 B MX390627 B MX 390627B MX 2019002265 A MX2019002265 A MX 2019002265A MX 2019002265 A MX2019002265 A MX 2019002265A MX 390627 B MX390627 B MX 390627B
Authority
MX
Mexico
Prior art keywords
functional capacity
pridopidine
functional
decreasing
treatment
Prior art date
Application number
MX2019002265A
Other languages
English (en)
Other versions
MX2019002265A (es
Inventor
Beth Borowsky
Eli Eyal
Igor D Grachev
Juha- Matti SAVOLA
Michael Hayden
Spyridon Papapetropoulos
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Publication of MX2019002265A publication Critical patent/MX2019002265A/es
Publication of MX390627B publication Critical patent/MX390627B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención proporciona un método para mantener la capacidad funcional, mejorar la capacidad funcional o retardar la disminución de la capacidad funcional en un paciente humano que comprende administrar periódicamente por vía oral al paciente una composición farmacéutica que comprende pridopidina de manera que se administre una dosis de 90-225 mg de pridopidina al paciente por día, para mantener así la capacidad funcional, mejorar la capacidad funcional o retardar la disminución de la capacidad funcional en el paciente humano.
MX2019002265A 2016-08-24 2017-08-24 Uso de pridopidina para el tratamiento de la disminucion funcional. MX390627B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662379175P 2016-08-24 2016-08-24
US201662395263P 2016-09-15 2016-09-15
US201662411511P 2016-10-21 2016-10-21
US201662416685P 2016-11-02 2016-11-02
PCT/US2017/048461 WO2018039477A1 (en) 2016-08-24 2017-08-24 Use of pridopidine for treating functional decline

Publications (2)

Publication Number Publication Date
MX2019002265A MX2019002265A (es) 2019-10-30
MX390627B true MX390627B (es) 2025-03-21

Family

ID=61241181

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019002265A MX390627B (es) 2016-08-24 2017-08-24 Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2022003072A MX2022003072A (es) 2016-08-24 2019-02-25 Uso de pridopidina para el tratamiento de la disminucion funcional.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022003072A MX2022003072A (es) 2016-08-24 2019-02-25 Uso de pridopidina para el tratamiento de la disminucion funcional.

Country Status (17)

Country Link
US (1) US11207310B2 (es)
EP (2) EP4516356A3 (es)
JP (2) JP6912574B2 (es)
CN (2) CN115671103A (es)
AU (2) AU2017315783C1 (es)
BR (1) BR112019003732A2 (es)
CA (2) CA3035092C (es)
CL (2) CL2019000485A1 (es)
DK (1) DK3504187T3 (es)
ES (1) ES3025836T3 (es)
FI (1) FI3504187T3 (es)
HU (1) HUE071008T2 (es)
IL (1) IL311081A (es)
MX (2) MX390627B (es)
PL (1) PL3504187T3 (es)
PT (1) PT3504187T (es)
WO (1) WO2018039477A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2611759A1 (en) 2010-09-03 2013-07-10 Ivax International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
SG11201509729YA (en) 2013-06-21 2015-12-30 Teva Pharmaceuticals Int Gmbh Use of high dose pridopidine for treating huntington's disease
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
MX378579B (es) 2015-02-25 2025-03-11 Prilenia Neurotherapeutics Ltd Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
EP4516356A3 (en) 2016-08-24 2025-05-14 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
MX2019002190A (es) 2016-08-24 2019-09-11 Prilenia Therapeutics Dev Ltd Uso de pridopidina para tratar distonías.
BR112019003320B1 (pt) 2016-09-15 2024-02-20 Boehringer Ingelheim International Gmbh Compostos de heteroaril carboxamida, sal farmaceuticamente aceitável dos mesmos, composição farmacêutica e seus usos como inibidores de ripk2
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
EP3678664A1 (en) 2017-09-08 2020-07-15 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
CN113365551A (zh) * 2019-01-31 2021-09-07 豪夫迈·罗氏有限公司 评估亨廷顿氏病的进展
WO2020161707A1 (en) 2019-02-04 2020-08-13 Prilenia Neurotherapeutics Ltd. Low dose pridopidine for parkinson's disease and other diseases associated with parkinsonism
HRP20260072T1 (hr) * 2019-06-12 2026-02-27 Prilenia Neurotherapeutics Ltd. Supstanca koja obuhvaća pridopidin i njegov analog za liječenje huntingtonove bolesti i njezinih simptoma
AU2021266476B2 (en) * 2020-05-04 2024-10-10 Prilenia Neurotherapeutics Ltd. Treatment of viral infection, disease or disorder using a selective S1R agonist
EP4322946A4 (en) * 2021-04-14 2025-02-26 Prilenia Neurotherapeutics Ltd. TREATMENT OF PRODROMAL HUNTINGTON'S DISEASE
WO2025164698A1 (ja) * 2024-01-31 2025-08-07 株式会社ケイファーマ ハンチントン病治療剤及び治療用組成物

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702716D0 (sv) 1997-07-15 1997-07-15 Ross Nicholas Waters Substituted phenylazacycloalkanes in the treatment of cognitive disorders
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
EP1713486A4 (en) * 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
GT200500063A (es) 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
WO2006040155A1 (en) 2004-10-13 2006-04-20 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
DOP2006000273A (es) 2005-12-08 2007-10-15 Aventis Pharma Inc Uso de un antagonista de cb1 para tratar efectos secundarios y sintomas negativos de la esquizofrenia
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
US20070286902A1 (en) 2006-06-07 2007-12-13 Abrika Pharmaceuticals Dosage forms comprising a short acting sedative-hypnotic or salt thereof
WO2008127188A1 (en) 2007-04-12 2008-10-23 Allbay Ab N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
US8669048B2 (en) * 2008-06-24 2014-03-11 Parkinson's Institute Pluripotent cell lines and methods of use thereof
US8384755B2 (en) 2009-08-26 2013-02-26 Intouch Technologies, Inc. Portable remote presence robot
KR101762460B1 (ko) 2009-09-24 2017-07-27 캡슈겔 벨지엄 엔브이 내산성 캡슐
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
US20130216856A1 (en) 2010-07-02 2013-08-22 Marco Burtchen Mechanical component and method of surface hardening
EP2611759A1 (en) 2010-09-03 2013-07-10 Ivax International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US8703763B2 (en) 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
EP2710041A4 (en) 2011-05-18 2014-11-05 Parkinson S Inst ASSAY FOR DETERMINING LRRK2 ACTIVITY IN MORBUS PARKINSON
CA2847736A1 (en) 2011-09-07 2013-03-14 IVAX International GmbH A new polymorphic form of pridopidine hydrochloride
TWI579272B (zh) 2011-12-08 2017-04-21 梯瓦製藥國際有限責任公司 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽
US9744155B2 (en) * 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
JP6177875B2 (ja) 2012-04-04 2017-08-09 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 併用療法のための医薬組成物
IN2015DN03219A (es) 2012-09-27 2015-10-02 Teva Pharma
WO2014052935A2 (en) 2012-09-27 2014-04-03 Teva Pharmaceutical Industries Ltd. Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
SG11201509729YA (en) * 2013-06-21 2015-12-30 Teva Pharmaceuticals Int Gmbh Use of high dose pridopidine for treating huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
EA201691454A1 (ru) 2014-01-22 2017-01-30 Тева Фармасьютикалз Интернэшнл Гмбх Композиции придопидина модифицированного высвобождения
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
CA2970799A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
MX378579B (es) 2015-02-25 2025-03-11 Prilenia Neurotherapeutics Ltd Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
CA2993183A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
WO2017048457A1 (en) 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
DK3419622T3 (da) 2016-02-24 2024-06-03 Prilenia Neurotherapeutics Ltd Behandling af neurodegenerativ øjensygdom med pridopidin
EP4516356A3 (en) 2016-08-24 2025-05-14 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
MX2019002190A (es) 2016-08-24 2019-09-11 Prilenia Therapeutics Dev Ltd Uso de pridopidina para tratar distonías.
US20200375966A1 (en) 2016-09-15 2020-12-03 Prilenia Therapeutics Development Ltd Use of pridopidine for the treatment of anxiety and depression
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
PL4005570T3 (pl) 2016-09-16 2024-09-23 Prilenia Neurotherapeutics Ltd. Pridopidyna do zastosowania w leczeniu zespołu retta
PL3570940T3 (pl) 2017-01-20 2024-06-17 Prilenia Neurotherapeutics Ltd. Pridopidyna do zastosowania w leczeniu zespołu łamliwego chromosomu x
EP4620471A3 (en) 2017-08-14 2025-11-26 Prilenia Neurotherapeutics Ltd. Treating amyotrophic lateral sclerosis with pridopidine
EA202090542A1 (ru) 2017-08-30 2020-06-08 Приления Ньюротерапьютикс Лтд. Высококонцентрированные лекарственные формы придопидина

Also Published As

Publication number Publication date
FI3504187T3 (fi) 2025-04-05
CA3035092A1 (en) 2018-03-01
WO2018039477A1 (en) 2018-03-01
PT3504187T (pt) 2025-05-09
PL3504187T3 (pl) 2025-06-09
IL311081A (en) 2024-04-01
CN115671103A (zh) 2023-02-03
AU2017315783C1 (en) 2020-12-24
AU2020223736B2 (en) 2022-04-07
US20180055832A1 (en) 2018-03-01
CA3151507C (en) 2024-05-28
NZ751156A (en) 2021-01-29
MX2022003072A (es) 2022-06-17
CA3035092C (en) 2022-05-31
CL2019000485A1 (es) 2019-07-12
CL2019003924A1 (es) 2020-05-29
JP2019524898A (ja) 2019-09-05
ES3025836T3 (en) 2025-06-09
EP4516356A2 (en) 2025-03-05
EP4516356A3 (en) 2025-05-14
CN109923102B (zh) 2022-11-15
JP6912574B2 (ja) 2021-08-04
CA3151507A1 (en) 2018-03-01
US11207310B2 (en) 2021-12-28
MX2019002265A (es) 2019-10-30
EP3504187A4 (en) 2020-05-06
JP2021119186A (ja) 2021-08-12
DK3504187T3 (da) 2025-04-14
HUE071008T2 (hu) 2025-07-28
BR112019003732A2 (pt) 2020-02-18
AU2020223736A1 (en) 2020-09-17
EP3504187B1 (en) 2025-02-19
AU2017315783B2 (en) 2020-05-28
EP3504187A1 (en) 2019-07-03
CN109923102A (zh) 2019-06-21
EP3504187B8 (en) 2025-03-26
AU2017315783A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
MX390627B (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX384234B (es) Uso de pridopidina para el tratamiento de enfermedad de huntington.
MX2024010140A (es) Nuevos metodos.
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
MX378579B (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX379286B (es) INHIBIDORES DE PCSK9 PARA USARSE EN EL TRATAMIENTO DE PACIENTES CON HIPERCOLESTEROLEMIA FAMILIAR HETEROCIGOTA (HFHe).
MX2021013139A (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
CR20180253A (es) Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
TW201613578A (en) Pharmaceutical combinations
PH12016502352A1 (en) Pharmaceutical composition
MX381440B (es) Composicion farmaceutica para tratar colitis ulcerativa.
MX379253B (es) Formulaciones de oximetazolina estabilizadas y sus usos.
MX374938B (es) Un método para el tratamiento de trastornos del movimiento con befiradol.
BR112015010223A2 (pt) compostos tricíclicos para o uso no tratamento e/ou controle de obesidade
BR112015015938A2 (pt) uso de cloridrato de fenilefrina e paracetamol, medicamento, método de tratamento de congestão das mucosas do trato respiratório superior em um humano adulto
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
MX2018004774A (es) Derivados de morfolina sustituidos que tienen actividad contra el dolor.
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.
ECSP19024033A (es) Composiciones de tesofensina
EA202090416A1 (ru) Способы лечения симптомов гастропареза с использованием велусетрага